Busca avançada
Ano de início
Entree


Engineering CAR-NK cells: how to tune innate killer cells for cancer immunotherapy

Texto completo
Autor(es):
Schmidt, Dayane ; Ebrahimabadi, Sima ; de Sena Gomes, Kauan Ribeiro ; Aguiar, Graziela de Moura ; Tirapelle, Mariane Cariati ; Silvestre, Renata Nacasaki ; Cottas de Azevedo, Julia Teixeira ; Covas, Dimas Tadeu ; Picanco-Castro, Virginia
Número total de Autores: 9
Tipo de documento: Artigo Científico
Fonte: IMMUNOTHERAPY ADVANCES; v. 2, n. 1, p. 14-pg., 2022-04-06.
Resumo

Cell therapy is an innovative approach that permits numerous possibilities in the field of cancer treatment. CAR-T cells have been successfully used in patients with hematologic relapsed/refractory. However, the need for autologous sources for T cells is still a major drawback. CAR-NK cells have emerged as a promising resource using allogeneic cells that could be established as an off-the-shelf treatment. NK cells can be obtained from various sources, such as peripheral blood (PB), bone marrow, umbilical cord blood (CB), and induced pluripotent stem cells (iPSC), as well as cell lines. Genetic engineering of NK cells to express different CAR constructs for hematological cancers and solid tumors has shown promising preclinical results and they are currently being explored in multiple clinical trials. Several strategies have been employed to improve CAR-NK-cell expansion and cytotoxicity efficiency. In this article, we review the latest achievements and progress made in the field of CAR-NK-cell therapy. (AU)

Processo FAPESP: 13/08135-2 - CTC - Centro de Terapia Celular
Beneficiário:Dimas Tadeu Covas
Modalidade de apoio: Auxílio à Pesquisa - Centros de Pesquisa, Inovação e Difusão - CEPIDs
Processo FAPESP: 19/25309-0 - NK-CAR (off-the-shelf) para o tratamento de Leucemias e Linfomas
Beneficiário:Virginia Picanço e Castro
Modalidade de apoio: Auxílio à Pesquisa - Regular
Processo FAPESP: 20/08279-8 - Estabelecimento de uma plataforma para geração de células NK-CAR com maior eficácia terapêutica in vitro e in vivo
Beneficiário:Júlia Teixeira Cottas de Azevedo
Modalidade de apoio: Bolsas no Brasil - Pós-Doutorado
Processo FAPESP: 20/09206-4 - Prospecção de rotas tecnológicas em imunoterapia na área de terapia gênica
Beneficiário:Kauan Ribeiro de Sena Gomes
Modalidade de apoio: Bolsas no Brasil - Doutorado